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-1ABSTRACT
Cancer, the second leading cause of death in the US, is caused by mutations in select
genes that alter cellular function leading to uncontrolled proliferation. Understanding the specific
genes that drive cancer can lead to the generation of novel cancer therapies. To identify novel
genes that drive cancer in the colon (CRC), lungs, and ovaries in mice, Starr et al. employed a
transposon-based insertional mutagenesis system. One of the genes identified, APC, is mutated
in 70-80% of human CRCs. CUL3, suspected to be a general driver gene, was discovered in the
lung cancer screen. CUL3 was analyzed for its role in a human CRC cell line in this study. CUL3
gene knockout was performed using the CRISPR/Cas9 system, which targets mutations to
specific genes, thereby knocking out that gene’s function. Three different sites in the CUL3 gene
were targeted for mutation and resulted in the creation of 41 separate cell lines with potential
CUL3 knockout. Of those 41 cell lines, 25 exhibited qualitatively abnormal phenotypes 10 days
after transfection. These phenotypes include slowed growth (25 of 25 cell lines), increased cell
size (16 of 25 cell lines), and variation of cell adherence to culture flask surface (11 of 25 cell
lines). Knockout was confirmed in 6 cell lines by using PCR in the region of the gene targeted
for mutation and sequencing the PCR product. Each cell line was quantitatively evaluated for
metabolic activity (or cell growth rate) using an MTS assay. If CUL3 knockout is shown to
reduce overall cell growth and increase susceptibility to chemotherapy, this would support the
development of new therapies for CRCs that target CUL3 function.

-2INTRODUCTION
PROJECT SIGNIFICANCE
Cancer is as pervasive as it is destructive. As the second leading cause of death in the US,
it has become a ubiquitous danger in today’s society (Murphy et al. 2013). Colorectal cancer
(cancer of either the colon or rectum) is the third most common cancer in both sexes, after
breast/prostate and lung cancers. According to the American Cancer Society, in 2014 an
estimated 96,830 new cases of colon cancer will be diagnosed, and 50,310 people are expected to
die of this disease. In an individual’s lifetime, it is estimated that they will have a 1 in 20 chance
of developing colorectal cancer. That’s 5% of the US population (American Cancer Society).
Current colon cancer treatments include surgery, radiation therapies, and chemotherapy.
Surgery is used to remove the portion of bowel that contains the tumor and is most the effective
treatment at earlier stage cancers. Radiation therapies use high energy light rays to destroy the
cancer cells. This is most commonly used when the tumor is in later stages and has invaded
another internal organ or abdomen lining, where surgery would be more difficult. It is also
commonly used when the cancer has spread, especially when it has spread to the bones or brain,
sites that are inoperable. Chemotherapy is the administration of drugs designed to kill quickly
dividing cells. In colorectal cancer, chemotherapy is mainly administered to patients post-surgery
to rid the body of any remaining tumor cells, as well as to those in advanced stages to lengthen
life-expectancy (American Cancer Society). These particular chemotherapies include standard
rapid growth inhibitors, like capecitabine (the first line treatment) and irinotecan (a second line
treatment), which inhibit RNA synthesis and DNA replication, respectively. They also include
monoclonal antibodies, which target epidermal growth factor receptors (EGFRs), often
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EGFRs (Cortejoso & Lopez-Fernandez 2012).
Depending on the stage, certain treatments are more effective. Stage I is almost
exclusively treated with surgery, and has a 5 year survival rate of 74%. Stages II and III usually
is a combination of treatments, with surgery when possible and radiation when not, as well as
chemotherapy. Both of these stages range in survival rates (II: 37%-67%; III: 28%-73%)
depending on the location of the tumor, the amount the tumor has invaded into other organs, and
whether or not it has reached the lymph system. Stage IV is the most fatal, as the cancer has
already spread to other organs and is often inoperable, which is why chemotherapy is often given
to slow the growth of the cancer. The survival rate for this cancer is 6% (American Cancer
Society).
Cancer is the result of multiple mutations (about 5-10) in select genes that allow cells to
rapidly divide and consume the body’s resources. These “driver” genes have often been reduced
to oncogenes and tumor suppressors, where oncogenes gain function to induce tumorigenesis and
tumor suppressors lose function to allow growth (Vogelstein & Kinzler 2004). However, with
the boom of genetic study following the Human Genome Project, other classes of genes that
affect tumorigenic growth have been identified. Hanahan and Weinberg have published more
than one paper entitled Hallmarks of Cancer with the goal of classifying potential tumorigenic
genes or cellular properties and widening our understanding of the genetic causes to cancer. In
their latest edition, published in 2011, they add four more hallmarks, bringing the total to 10.
These include, but are not limited to, properties that induce angiogenesis, increase genome
instability, resist growth suppressors, and avoid immune response. By recognizing the driver
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create swifter and more effective treatment.
The most famous (and very effective) targeted cancer driver therapy is the drug
Herceptin. It specifically interferes with the gene HER2, which is commonly mutated in breast
cancer, as well as other cancers. The mutation results in the overexpression of the HER2 protein
receptor on the outside of the cells that, when activated, signals the cell to start dividing.
Herceptin interrupts this pathway by blocking the receptor so that the cell cannot receive the
signal to divide. The drug has been shown to be extremely effective on late-stage and spreading
cancers, helping those who would not benefit from more traditional therapies. (Herceptin).
This research, like the Herceptin research, could be the stepping stone to creating more
specific cancer drugs with fewer side effects. By knowing what genetic mutations help or hinder
tumorigenesis, we may be able target those pathways to slow the cancer’s growth, giving patients
more time and options.

TRANSPOSON-BASED INSERTIONAL MUTAGENESIS
Transposon-Based Insertional Mutagenesis
There are various ways to induce tumorigenesis in models to study cancer. Until recently
retroviral insertional mutagenesis was the method of choice, as it allowed for rapid tumor
induction and high throughput. However, this method is not truly random, as the proviral DNA
has tendencies to integrate at the 5’ ends of genes. It can also affect the promotion of oncogenes
hundreds of kilobases away by way of an enhancer within the proviral DNA, making it difficult
to determine which gene the insertion is truly affecting (Copeland and Jenkins 2010). Since this
method of tumorigenesis does not lend itself to accurate biostatistical analysis, another rapid,
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(TIM).
DNA-only transposons are short segments of DNA that can move randomly within the
genome. Traditionally, these transposons move on their own, coding for their own excision and
integration enzyme, called a transposase, within the transposable element. However, nonautonomous transposons have been experimentally created, and are able to be controlled by
providing the transposase in trans, i.e. separate from the transposable element (Copeland and
Jenkins 2010). Multiple copies of the transposon within the genome ensures high rates of
mutative transposition, as there is a 30-40% chance that the transposon will not reintegrate after
excision (Copeland and Jenkins 2010).
The Sleeping Beauty (SB) transposon is one of those that have been used to induce
cancer in mice. It was originally seen in fish, xenopus, and even human genomes, however,
generations of mutations left the transposase catalytically inactive. Ivics et al. (1997)
reconstructed the transposase and “awoke” the transposon from evolutionary sleep, allowing its
transposition to occur again. Its mobility in mammalian species made it an excellent candidate
for alteration for research use.

Figure 1. The layout of the T2/Onc2 transposon. The DNA-only transposon is capped with inverted repeats (the
black arrows at the ends) and includes two splicing acceptor sites (SA) and a splicing donor site (SD); a murine stem
cell virus (MCSV LTR) promoter; and a poly-adenine tail sequence (pA).

To utilize the SB transposon as a cancer inducer, Dupuy et al. created the T2/Onc2
transposon (2005) (Figure 1). It contains a murine stem cell virus long terminal repeat (MSCV
LTR) to activate transcription and a polyadenylation tail to signal the early termination of
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of the intended targets. Breeding the T2/Onc2 transgenic mice with another transgenic strain,
known as RosaSB, which expressed the SB11 transposase ubiquitously in all tissues, led to
double transgenic mice that have the ability to mobilize the T2/Onc2 transposon. Unfortunately
(or fortunately) for Dupuy et al., the transposon/transposase combination worked too well –
many transgenic mice died as embryos due to lethal mutations caused by the transposon system
(2005). Of the 24 mice that survived weaning, all had died of cancer (mostly blood cancers) by
17 weeks.
Transposon Use for Discovery of CRC Driver Genes
In 2009, Dr. Starr and a team of researchers at the University of Minnesota published a
paper that utilized TIM to create a murine model of colorectal cancer. They bred a line of
transgenic mice from three others: RosaSB, VillinCre, and T2/Onc. The RosaSB and VillinCre
mice were first bred together. The offspring from this mating had transposase expression that
was exclusive to the epithelium of the colon. This double-transgenic mouse was then bred with
the T2/Onc mouse to create the triple-transgenic line that contained the directed transposase and
25 copies of the T2/Onc2 transposon. The mice were then watched for 18 months, or until they
passed away from colorectal cancer at which time the tumors were then harvested and
genotyped. The location of each transposon insertion was determined. Genomic analysis was
performed on all insertion sites and a catalogue of driver versus passenger mutation was created
based off of biostatistics on the likelihood of multiple insertions being randomly close together in
the genome. Of the 135 tumors harvested, 16,690 insertion sites were catalogued. From thse
insertion sites, 77 genes were found to be likely colorectal cancer driver genes.
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70% of colorectal cancers and serves as a proof-of-concept discovery. While many of the genes
identified have already been catalogued, many had not been previously linked to colorectal
cancer.
Dr. Starr has since repeated this process in lung and ovarian cancers in mice (Starr,
unpublished). CUL3 was found to be a driver gene in lung cancers, though further study
indicates that CUL3 may be a general cancer driver gene, and was hence used in this study to
determine if it may have a role in CRC development.
CUL3 FUNCTION AND ITS POTENTIAL ROLE IN CANCER
Ubiquitination and Protein Degradation
Ubiquitination is the process of attaching the small protein, called ubiquitin, to a protein
to affect its function. The attachment of ubiquitin to target proteins involves three mediating
enzymes: ubiquitin-activating enzyme
(E1), ubiquitin-conjugating enzyme (E2),
and ubiquitin ligase (E3) (Figure 2).
While there are few types of E1 and E2s,
E3s are the most diverse group of
ubiquitination enzymes, with over 500 E3
ligases identified (Andérica-Romero et
al. 2013). The more common process of
polyubiquitination marks proteins for
degradation, while monoubiquitination is

Figure 2. Schematic of Ubiquitin Ligation. (Adapted from
Andérica-Romero et al. 2013) Ubiquitination requires more than
just the ligase. Above, the ligase uses an adapter to bind to the
target protein. Nedd8 is a neddylation factor (see pg. 12) that
alters ligase function, Ub is the ubiquitin, and E2 is the Ubconjugating enzyme.
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monoubiquitination).
Ubiquitin-dependent degradation is performed by the 26S proteasome complex. The
complex is a conglomeration of proteases that create a cylindrical tube of catalytic activity,
capped by a regulatory “lid” that protects cytosolic proteins from accidentally entering the
catalytic cylinder. The proteasome lid recognizes the ubiquitin and unwinds the target protein,
feeding it through the cylinder, where the protein is degraded into short peptides for reuse
(Voges et al. 1999). The complex is ATP-dependent and responsible for 80-90% of cellular
protein degradation (Thompson et al. 2008, Voges et al. 1999). While ubiquitination has long
been associated with apoptosis, the process is also integral in cell-fate specification,
transcription, and cell cycle progression.
CUL3 Ubiquitination
CUL3 is a gene located on chromosome 2 in the human genome, and the gene of interest
for this study. It codes for the cullin 3 protein, which has a major role in polyubiquitination.
Cullin 3 falls into the more common class of ubiquitin ligases, the cullins. The cullins are often
referred to as CRLs, or cullin-RING ubiquitin ligases. Ubiquitination by way of CUL ligase is
not exclusive to one protein, or even a family of proteins. It has many different substrates at
many different stages of life. As a result, issues with CUL3 affects a cascade of different proteins
and cellular processes. A few substrates of the ligase are well known, but many more are
probably yet to be discovered (Andérica-Romero et al. 2013).
One known CUL3 ligand is the MEI1 protein involved in cell division. This particular
protein is used in gamete formation primarily, as it signals the formation of a meiotic spindle.
However, its creation and subsequent degradation is also required for the functional assembly of
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2004). Without CUL3
polyubiquitination and
degradation, the mitotic spindle
will form much more similarly to
a meiotic spindle, where the
spindle is formed on one side of
the cell and uneven cleavage

Figure 3. Effects of CUL3 knockout on mitotic spindle formation. (Pintard
et al. 2004; Used with permissions from Wiley Online Library) CUL3
knockout eliminated MEI1 degradation from the cell cycle, allowing the
mitotic spindle to form more similarly to the meiotic spindle.

along the divisional plane occurs (Pintard et al. 2004). The result is two unequally sized daughter
cells (Figure 3). Unfortunately, nearly all data surrounding inquiry into this protein comes from
Caenorhabditis elegans zygotes, though there is a human homolog.
CUL3 also targets Nrf2 (Nuclear-factor erythroid-derived-2-like 2), a transcription factor
involved in the response to oxidative stress. During homeostasis, Nrf2 is constantly bound to
KEAP1, an adapter protein that facilitates CUL3 targeting (Zhang et al. 2004A) Nrf2 is then
ubiquitinated and degraded by the 26S proteasome. This process of rapid creation and
degradation (turnover of about 20 minutes) continues until the cell undergoes oxidative stress,
after which Nrf2 is allowed to aid in the transcription of many different proteins that respond to
such a stress (Kobayashi et al. 2004; Zhang et al. 2004A). Overexpression of Nrf2 has been seen
to aid in glioma resistance to the chemotherapy carmustine, though these results are only seen in
neurological and immune cell cancers as these are the only cancers in which carmustine is used
(Sukumari-Ramesh et al. 2015). In gastric cancers, Nrf2 expression has been directly correlated
with cancer aggressiveness (Kawasaki et al. 2015).
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complex that releases torsional stress on DNA during replication. Topoisomerase I (TOP1) is the
main target of camptothecin (CPT)-type chemotherapies, two of which (topotecan and
irinotecan) are currently FDA-approved. A knockout in CUL3 should increase the amount of
TOP1 in the cell as there is no degradation machinery available to eliminate it. In fact,
overexpression of CUL3 has been shown to induce resistance to CPT chemotherapies by way of
down-regulation of TOP1, the target of CPTs (Zhang et al. 2004B, Beretta et al. 2013).
CUL3 has also been recently
implicated in having a role in mitotic
spindle stability and localization of
chromosomes during anaphase.
However, CUL3 does this through
monoubiquitination (a process that has
only two known CUL3 substrates) rather
than polyubiquitination. This single
ubiquitin is not enough to signal for
proteasomal degradation, but instead
simply alters protein function (Maerki et

Figure 4. Abnormal microtubule formation with Aurora B
kinase inhibition. (Kallio et al. 2002; Used with permissions
from Elsevier) Anti-Aurora B antibody injection results in
abnormal microtubule formation and mis-localized
chromosomes. The yellow arrow shows at least one
chromosome off of the divisional plane. The white arrows
point to centrosome location.

al. 2010). The target is Aurora B kinase, a component of the Chromosomal Passenger Complex
(CPC). The CPC localizes to chromosomes at the beginning of mitosis and to the spindle
microtubules as anaphase begins to ensure proper cytokinesis (Maerki et al. 2009, 2010).
Monoubiquitination is critical for localization to the spindle. It has been suggested that
ubiquitination allows Aurora B and the CPC to bind to the microtubules by way of an ubiquitin
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Additionally, there is evidence that ubiquitination allows dissociation from mitotic chromosomes
in the first place to allow secondary localization (Sumara et al. 2007). Localization is critical to
properly cleave the cells, and failure to localize results in multinucleated cells (Maerki et al.
2009). Additionally, there is evidence that Aurora B inhibition results in more astral microtubule
formation (deriving from the centrosome but not connecting to a kinetochore) and more fragile
spindles in general (Kallio et al. 2002) (Figure 4). It should be noted that, unlike other substrates
of CUL3 where knockout would result in their overexpression, CUL3 knockout effectively
knocks out Aurora B function.
Notably, CUL3 has also been implicated in cyclin E degradation (Singer et al. 1999).
Cyclin E is responsible for cell cycle control. Its attachment to Cdk2 (cyclin-dependent kinase)
regulates cell cycle transitions (Hwang & Clurman 2005). The amount of free cyclin E during
cell cycle transitions, which is often used as an indicator of Cdk2 activity, has best been
characterized at the exit of G1 and the duration of S phase. Increased cyclin E expression is often
the herald of the end of G1, often working in tandem with other mitogenic signals (Singer et al.
1999). Additionally, its abundance during S phase is inversely correlated with the duration of S
phase (Hwang & Clurman 2005). CUL3 targets cyclin E in its unbound form, but if the
ubiquitination process is interrupted, by CUL3 knockout or 26S proteasome inhibition, the cell
cycle timing becomes disrupted. G1 is much shorter due to the abundance of cyclin E. The cells
also spend more time in S phase than a normal cell (Singer et al. 1999, Hwang & Clurman 2005).
In addition to changes in duration of the cycle phases, there is also evidence that upregulation of cyclin E results in more genetic instability. This implies that expression of cyclin E
may increase the mutagenic and oncogenic properties of any given cell. It also gives some
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show a negative correlation between cyclin E expression and positive patient outcome, giving an
effective diagnostic tool for evaluating cancer prognosis. Keyomarsi et al. (2002) found that
patients with early stage breast cancers with high cyclin E expression all died within five years of
diagnosis (12/12), while similar patients with low cyclin E expression all survived the five year
mark (102/102). It has been shown, however, that cyclin E production is not directly correlated
with speed of cancer growth in patients (Hwang & Clurman 2005).
What should also be noted is that CUL3 itself is regulated in many ways. Various BTBdomain (bricabrac-tramtrack-broad complex) Kelch-like proteins function as different adaptor
proteins to target CUL3 to the specific protein of interest (seen in Figure 2). The BTB domain
binds to the ligase while the Kelch domain binds to the substrate (Canning et al. 2013). Without
these adapter proteins, CUL3 is unable to bind to target proteins and thus cannot catalyze
ubiquitin attachment (Xu et al. 2003). For example, MEL26 is an adapter protein for MEI1. A C.
elegans embryo with a MEL26 knockout expresses the same abnormal mitotic spindle expressed
in a CUL3 knockout embryo (Pintard et al. 2004, Xu et al. 2003). When it comes to potential
treatment avenues, individual BTB adaptor proteins could be targeted rather than CUL3 itself to
ensure specific and effective treatment.
CUL3 is also regulated on larger scales by neddylation and deneddylation – attachment
of Nedd8 to change the conformation of CUL3 and affect its function (Parry and Estelle 2004).
While in reference to a CUL3 knockout neddylation patterns shouldn’t affect much,
overexpression of CUL3 would be more susceptible to Nedd8 alteration (see Figure 2).
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While CUL3 was implicated in murine lung cancer by Dr. Starr, the link of CUL3 to
colorectal cancer is relatively unknown. The COSMIC (Catalogue of somatic mutations in
cancer) database has one entry regarding colon cancer and CUL3, although it does have 34 listed
entries that corroborate CUL3 as a general cancer driver gene (most of this information comes
from unpublished data dumps, including the data regarding the gene’s involvement in colon
cancer).
An effective method of determining the role of a gene to cancer is to perform a knockout.
This essentially mutates a gene to the point where the protein product is no longer functional.
With a CUL3 knockout cell line, we may be able to evaluate CUL3’s importance to cancer in a
more meaningful way. A new method of performing a knockout (and the one used in this study)
is the CRISPR/Cas9 system.

CRISPR/CAS9 AND GENE KNOCKOUT
The Discovery of CRISPR/Cas9
The CRISPR/Cas9 system was originally discovered in archaea and bacteria, which use
the system as a defense mechanism against invading viral DNA and plasmids. It has been most
extensively studied in the bacterial species Streptococcus pyogenes. Jinek et al. (2012) proposed
its utilization as a biotechnological tool for DNA editing, as it is easily programmable and very
specific.
In the single-cell organisms from which this system was derived, the viral DNA is
integrated into the organism’s own genome to target that same virus at the next instance of
infection. Once the invading DNA enters the cell, it gets fragmented into protospacers which are
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so that they come directly after the repeat sequence (Jinek et al. 2012). The cell now has multiple
recognition sequences (spacers) targeting known invasive DNA, which can direct DNA silencing
with Cas (CRISPR-associated) cutting enzymes (Figure 5). At the next instance of viral invasion,
the Cas enzymes and the multiple
spacer/repeat sequences, or crRNAs will be
transcribed. The Cas enzymes, after
translation, will align with the crRNA and
the complex will meet the viral invader. If
the crRNA sequence aligns with the viral
DNA, the Cas enzymes will catalyze a blunt
cut, inactivating the viral DNA and
allowing its digestion by other nucleases

Figure 5. Diagram of CRISPR array and protospacer insertion in
bacteria. (Adapted from Kyoto University Laboratory of Bacterial
Infection) (Proto)spacers are integrated into a bacterial genome to
directly follow the CRISPR repeat sequences.

(Jinek et al. 2012, Mali et al. 2013, Ran et
al. 2013).
While there are three types of CRISPR/Cas systems, the type II system has been the
subject of further study with regards to biotechnological use. This is due to the fact that it
requires only one Cas protein - specifically Cas9 - instead of a multi-Cas protein complex, like
types I and III. In types I and III, the raw crRNA is altered by one Cas protein, and cleavage is
caused by multiple other Cas proteins formed into a complex. Type II requires only one Cas
enzyme (Cas9) because of the utilization of a second RNA, a trans-activating crRNA, or
tracrRNA, that base pairs to the repeat sequence of the crRNA (Jinek et al. 2012).
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involves the protospacer’s placement within the invasive DNA relative to a short specific
nucleotide sequence, known as the PAM, or protospacer adjacent motif. For S. pyogenes, this
sequence is NGG, placed three nucleotides upstream of the protospacer within the invasive DNA
(Jinek et al. 2012).
The Use of CRISPR/Cas9 for Gene Knockout
The CRISPR/Cas9 system has become increasingly popular as a method of genome
editing. It has all but replaced zinc-finger nucleases (ZFNs) and transcription activator-like
effector nucleases (TALENs) as the go-to system for genome editing and gene knockout. These
two systems have similar endonuclease activity to CRISPR/Cas9, but they take longer to make
and are less effective overall. From start to finish, a CRISPR/Cas9 knockout can take only a
month to complete (Ran et al. 2013). This study took two months.
To use the CRISPR/Cas9 system, certain changes needed to be made to the bacteria’s
system. The most obvious was to place the important pieces into a vector to place it into desired
cells. Two options currently exist: one is plasmid vectors that are transfected into the organism of
choice, and the other is a viral vector. Lentivirus is preferred here, as it can infect live hosts and
dividing cells, ideal for animal modeling. Additionally the crRNA and tracrRNA portions were
fused by a hairpin loop, making one long single guide RNA, or sgRNA, which only requires one
template (Jinek et al. 2012; Hwang et al. 2013). The beauty of the CRISPR/Cas system is its
genetic brevity, making vector transfection rather simple.
Lastly, targeting to the gene of interest is needed. This involves finding an approximately
20 bp section (protospacer) within the mRNA of the desired gene that is three base pairs
downstream of a specific PAM sequence (Figure 6). The number of base pairs between the

- 16 protospacer and the PAM and
the exact PAM sequence is
dependent on the organism of
derivation of the sgRNA and
the Cas9 enzyme, as they vary
from species to species (Jinek et
al. 2012). After the target
sequence is chosen, this
sequence is added to the 5’ end
of the sgRNA template to create

Figure 6. Configuration of sgRNA and Cas9 with genomic DNA. (Hwang et
al. 2013; Used with permissions from the Nature Publishing Group) Above
shows the structure of the sgRNA and how it targets within the genome. Note
the PAM sequence NGG directly downstream of the target site.

the spacer. The spacer is the only portion of the entire CRISPR/Cas9 complex that changes from
target to target (Jinek et al. 2012; Mail et al. 2013). Depending on the target cells, whether they
are human or mouse or other, the Cas9 enzyme coding sequence is often altered to optimize for
the codons commonly used in the organism of interest. Additionally, human (or other
organism’s) promoters are used at the beginning of the Cas9 and the sgRNA sequences to ensure
constitutive expression once within the cells. For example the human U6 polymerase III
promoter is commonly used in front of the sgRNA when transfecting human cell lines in vitro
(Mali et al. 2013).
Once the cells have been transfected, either by viral vector or plasmid (as was used in this
study), the system uses the cell’s own internal machinery to transcribe the Cas9 enzyme and the
sgRNA, aided by the humanized promoters. The Cas9 enzyme associates with the crRNA and
tracrRNA domains of the sgRNA. The Cas/sgRNA complex then aligns with the protospacer and
the PAM sequence while holding apart the two strands of the target DNA. The Cas9 enzyme
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result in a mutation when rejoined by non-homologous end joining (NHEJ) (Ran et al. 2013).
NHEJ is used when both DNA strands are cut and a DNA template for the region is unavailable.
It involves the recruitment of various capping proteins that bring the two ends together and a
ligase (ligase IV) to reconnect the strands. It often results in frameshift mutation, as some
nucleotides can be lost during DNA cleavage or inserted in the repair process (van Gent & van
der Burg 2007).
If mutation does not occur during DNA repair, the system will repeat the process, as long
as the spacer can still recognize the protospacer (Hsu et al. 2013). This process also ensures
DNA mutation as long as the templates for both the Cas9 enzyme and the sgRNA plasmids were
successfully transfected into the cell.
Off-Target Effects
While the system is specific and efficient, there is also the possibility of off-target effects,
as there are with any nuclease. The number of off-target sites and the frequency of off-target
cutting is dependent on the sgRNA sequence chosen. Obviously if the target sequence exists in
more than one place in the genome, Cas9 with catalyze cleavage at both sites about equally. Ran
et al. (2013) found that some level of mismatch is allowed in sgRNA base pairing with its target.
For the most part, only three or less mismatches in the 20 bp sequence, or 85% or more sequence
homology, is tolerated. Additionally, mismatches are more tolerated at the 3’ end of the
sequence. The frequency of mismatch base-pairing is also dependent on the concentration of
Cas9 and sgRNA transfected into the cells, as well as their ratios. The frequency of off-target
cutting increases as the concentration of Cas9 plasmid dosage at initial transfection increases
(Hsu et al. 2013).

- 18 The easiest way to prevent off-target effects is to carefully select the sgRNA sequence.
Certain design databases such as ZiFiT (Sander et al. 2010) and the CRISPR Design Tool
(http://tools.genome-engineering.org) will give the most likely off-target sites with every
potential target sequence. However, they are still possible even with the greatest precautions and
should therefore be analyzed in all uses of CRISPR/Cas9.

PURPOSE OF STUDY
CUL3 has been shown to be an important driver gene in lung tumorigenesis in mice. Due
to the implications that this gene is a general cancer driver gene, CUL3 is likely also important in
human CRC development. CUL3 ligase has many different known substrates – some of which
may have effects on cell health and cancer proliferation. We have attempted to evaluate the
importance of CUL3 to human CRC using CRISPR/Cas9 based CUL3 knockout in the HCT-116
human colorectal cancer cell.

- 19 METHODS
Cell Culture
HCT-116 cells were cultured at 37° C and 5% CO2 in DMEM (Dulbecco’s Modified
Eagle Medium) (Gibco, Grand Island NY), supplemented with 1% L-Glutamine (Gibco, Grand
Island NY), 1% Penicillin/Streptomycin/Fungizone (PSF) (Gibco, Grand Island NY), 2.5%
HEPES buffer (Gibco, Grand Island NY), and 10% Fetal Bovine Serum (FBS). Cells were stored
frozen in FBS containing 10% DMSO (Dimethyl sulfoxide) (Sigma-Aldrich, St. Louis MO) and
cryopreserved in liquid nitrogen until needed. When cells were passed, they were first removed
from culture flasks by treatment with 0.5% Trypsin-EDTA (Gibco, Grand Island NY) for 10
minutes. After trypsin neutralization, they were diluted 1:20 in their new flask, unless an
abnormal (slowed) growth phenotype was seen, in which case they were passed 1:10.
Puromycin Assay
The HCT-116 cells were plated at a 1:10 dilution in a 96-well plate and allowed to grow
up for three days. After the cells had reached 80-90% confluence, the media of some wells was
removed and replaced with puromycin media at various concentrations of puromycin: 10 ug/mL,
5 ug/mL, 2.5 ug/mL, 1.25 ug/mL, .625 ug/mL and 0 ug/mL. Four replicates of each
concentration were created in the plate. Every 24 hours after the initial media replacement, one
well of each concentration was removed and counted by trypan blue exclusion. At the end of
three days, the minimum concentration that produced complete death was chosen. In this
experiment, 1 ug/mL of puromycin was chosen for subsequent selection steps. This
concentration is consistent with the 1 ug/mL concentration used by Dr. Starr at the University of
Minnesota for this cell line.
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HCT-116 cells were plated in a 24-well plate and allowed to grow until at 60-70%
confluence, or about two days. After confluence had been achieved, the cells were transfected
with two plasmids: the Piggy-BAC puromycin resistance plasmid and the pB7 transposase
plasmid. To determine the ideal concentration of the transfection chemical, Lipofectamine
(Invitrogen, Carlsbad CA), the cells were transfected with varying concentrations (1uL, 1.5 uL,
2uL, and 2.5 uL/mL media) of Lipofectamine. Each well was given .25 mg of each plasmid per
mL. Prior to transfection, the plasmids and Lipofectamine incubated in OptiMEM media for 5
minutes to ensure full coating of the plasmids in the Lipofectamine. The Lipofectamine-plasmid
complex was then added to the media of 2 wells (per concentration) of the 24-well plate (see
Appendix 5). After the addition of the Lipofectamine-plasmid complex, the cells were allowed to
recuperate and grow for 24 hours. This also allowed enough time for the cells to take up the
antibiotic resistance plasmids and become puromycin-resistant. After this 24 hour period, the
media of the transfected cells was replaced with media containing puromycin at the
predetermined 1 ug/mL concentration. The cells were allowed to sit in the puromycin for four
days undisturbed. After this 4 day period, the cells were analyzed for overall confluency.
Optimal Lipofectamine dilution was chosen based on which concentration produced the highest
number of transfected (puromycin resistant) cells.
Confluency Assay
HCT-116 cells were plated in 4-well increments at varying concentrations ranging from
100-5000 cells per well. They were allowed to grow up for four days. After this time, overall
confluency was recorded. The lowest concentration that resulted in an average of approximately
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cells per well.
U6-sgRNA Plasmid Design
Plasmid design was performed by Dr. Goldberg’s lab in the summer of 2013. The empty
U6-sgRNA plasmids (without a target sequence introduced) were obtained from Dr. Starr at the
University of Minnesota. Inverse primer design was performed using the ZiFiT computer
program, which locates multiple target sequences within the target gene that also has the PAM
sequence directly after the target DNA (Sander et al. 2010). In this study, the CRISPR/Cas9
system was derived from S. pyogenes, making the PAM sequence NGG. The plasmids were
created using Inverse PCR and frozen in nuclease-free water at -20° C until use in 2014.
CRISPR/Cas9 Knockout
HCT-116 cells were plated in a 24-well plate and allowed to grow two days until they
reached 60-70% confluency. After this time, the cells were transfected using the predetermined
Lipofectamine concentration. Four plasmids were placed in each well: the Piggy-BAC
transposon with puromycin resistance, the pB7 transposase plasmid, the Cas9 endonuclease
plasmid, and the pU6 RNA guide sequence. Three different U6 guide sequences were created
previously to target the CUL3 gene. Two wells of the 24-well plate were transfected for each
pU6 plasmid. The Piggy-BAC and pB7 were still at 0.25 ug per well, but the Cas9 and the pU6
were added at 1 ug per well in an effort to ensure that every colony that received antibiotic
resistance would also likely have the knockout. After Lipofectamine-plasmid complex
incubation, the wells were transfected and allowed to grow up an additional 24 hours before
subcloning.
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24 hours after transfection, the transfected cells were removed from the 24-well plate and
replated in 96-wells in 1 ug/mL puromycin media at low density (2000-3000 cells per well),
determined by the confluency assay. After 8 days of incubation with puromycin media, clonal
colonies were selected by locating wells with a single colony that had arisen from a single cell.
Over the next month, selected cell lines were removed from their wells when appropriate (6070% confluency) using 0.5% Trypsin-EDTA incubated for 5-15 minutes. They were placed into
a larger culture container until they could maintain normal growth in a 25 mL culture flask. At
this point, cells were partitioned off for DNA extraction and freezing.
Imaging
All images were captured with an inverted light microscope set at 100x connected to an
iPhone 5 (2013). Images were adjusted to improve clarity by Windows Photos (2014).
DNA Extraction
DNA extraction was performed with the Promega Wizard Genomic DNA Purification Kit
(Madison, WI). Resulting DNA purity and concentration was determined with a Nanodrop 2000.
Primer Design and PCR
Primers were designed by hand using the genomic CUL3 DNA sequence from NCBI
Blast. Primer alignment was confirmed using PrimerQuest and IDT (Integrated DNA
Technologies) Primer Design. Primers were obtained from IDT (Coralville IA) as standard
desalted oligos (sequences in Appendix 1).
PCR was performed using Gotaq Green Master Mix (Promega, Madison WI), the
previously mentioned primers and extracted DNA to amplify the regions of intended knockout
for sequencing as per Gotaq protocols (see Appendix 3). PCR was performed using an
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using the program outlined in Appendix 2.
Confirmation of successful PCR was done by gel electrophoresis. PCR product was run
on a 1% agarose gel using a BioRad MiniSub® Cell GT Cell horizontal gel box and compared to
a Bioline (Boston MA) 50 bp ladder. The gel was imaged with a BioRad GelDoc XR+ UV
transilluminator to ascertain appropriate band length and PCR product amount.
PCR product was purified using the Promega SV Gel and PCR Clean-Up System
(Madison WI). Resultant products were maintained in the provided EB buffer before sequencing.
Sequencing and Confirming Knockout
Sequencing of PCR products was performed by Functional Biosciences (Madison, WI).
The sequencing results of all cell lines created using the P1 sgRNA guide plasmid were aligned
using ClustalW to look for genetic inconsistencies between the Ctrl (parental) sequence and the
various transfected cell lines. Any nucleotide differences within 10 bp of the supposed target site
from the parental HCT-116 DNA sequence was considered to be a confirmed knockout.
MTS Assay
HCT-116 cells were plated at low density, previously determined by the confluency
assay, in 12 wells of a 96-well plate, placed in 2 rows of 6 wells. Four plates per cell line were
created to take data over a four day span. Each day, one plate was used for analysis. 6 of the 12
wells per cell line had 20 uL of Promega AQueous ONE CellTiter MTS Liquid (Madison, WI)
added, and all used plates were placed back into the incubator for four hours to allow
colorimetric development. The 12 wells were measured with a plate reader at both 490 nm and
650 nm. This process was repeated for four straight days to determine changes in metabolic rate
over time.
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Potential sites of off-target cutting for Cas9 construct #1 were determined using an NCBI
Blast search for the primer and PAM sequence. The PAM sequence used was both NGG and
NAG, as Hsu et al. found that both PAMs can be recognized for off-target cutting (2013). Any
result below 80% homology was also excluded based on Hsu et al.’s findings.
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Various Experimental Assays
As the mutant cells should carry puromycin resistance after transfection, an ideal
concentration of puromycin, one that would allow complete death of all non-resistant cells (e.g.
non-transfected cells) in 4 days, with the lowest concentration possible to avoid damaging the
mutant cells, was required. This was determined by exposing wells of HCT 116 to varying
concentrations of puromycin and recording the percent viability daily for three days. As shown, a
concentration of 1.25 ug/mL or above of puromycin is ideal to see total death after three days
(Figure 7). This study required four or more days in puromycin, though the data was taken over
three days. As 1.25 ug/mL was effective after three days, and 0.625 ug/mL showed little-to-no
change after three days, our results were in the range of the Starr lab’s experimentally
determined value of 1 ug/mL, which was used in further experiments.

Effects of Increasing Concentrations of Puromycin on the
Viability of HCT116 Cells over Time
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Figure 7. Percent Viability of Cells based on Puromycin Concentration. Percent viability was determined over 3
days by trypan blue exclusion. A concentration that produced total death after four days is ideal.
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Effects of Varying Lipofectamine Concentrations on
Transfection Efficiency in Several Human CRC Cell Lines
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Figure 8. Lipofectamine Assay. Three colorectal cancer cell lines were transfected with puromycin antibiotic
resistance plasmids with varying concentrations of Lipofectamine. After four days of treatment with puromycin,
the confluency of the treated wells was determined.

The ideal concentration of lipofectamine, the chemical used in transfection, was
determined by transfecting CRC cells at varying concentrations of lipofectamine and the
puromycin resistance plasmids, and then subsequently incubated in the previously determined
puromycin concentration. A concentration too low would not allow all transfection possible and
a concentration too high could prove toxic to the cell. This assay was performed not only with
HCT-116, the cell line used in this study, but with DLD-1 and HT-29 as well, two other CRC
cell lines that, in the future, may also be

Conc: 1 uL/mL

1.5

2

2.5

mutated and evaluated (Figure 8). As shown,
a lipofectamine concentration of 1.5 uL/mL
media was determined to be ideal for all
three cell lines. For HCT-116, Figure 9
shows the raw confluency and number of

Figure 9. HCT-116 Lipofectamine Assay results. Results were
taken on Day 4 of the assay. In red, confluency of the well is
shown. In blue, the number of individual colonies is shown.

- 27 colonies data four days post transfection and puromycin treatment.
To ensure the cells
were plated at a low
enough concentration to
achieve the desired oneliving-cell-per-well ideally
needed to create individual
clonal cell lines, a
confluency assay was
performed. The goal was to
determine the concentration
of cells that would take

Figure 8. Confluency assay results of HCT-116. Cells were plated at varying
concentrations (100-5000 cells/well) and grown for four days. The above results
show the approximate confluency in that time. For HCT-116, approximately
2500 (or 2000-3000) cells per well achieved an ideal confluency (approximately
85-90%) after four days.

four days to achieve a confluency of 85-90% (Results in Figure 10). Cells were plated at initial
concentrations varying from 100-5000 cells per well in a 96-well plate. A 96-well plate was used
because that was the plate to be used to start our clonal colonies. After four days of growth at
varying concentrations, the ideal concentration chosen was between 2000 to 3000 cells. Previous
plating attempts showed that a concentration closer to 3000 cells/well was too concentrated to
produce single clonal colonies in one well at a high enough frequency, so for our purposes,
transfected cells were plated at an initial concentration closer to 2000 cells/well. Anecdotally,
nearly all wells found to have any living cells contained single clonal colonies, with only a
handful of wells containing two or three colonies. The 41 cell lines obtained were from 6 plates
(or 576 total wells), and no single clonal colony was left out.
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Parental

Growth Speed
(approximate)
Fast

Abnormal
Morphology?
No

1MY1
1MY2

Medium
Medium

Yes
Yes

1SY1

Slow

Yes

1SY2
1SY5

Slow
Slow

Yes
Yes

1SSY2

Super Slow

Yes

Cell Line

Extra-Large
Cells

Abnormal
Adherance

*
*
+
+
+
+

Table 1. Parental and confirmed knockout cell line observational data. Cell lines are categorized at various
growth speeds and whether or not they exhibited abnormal morphology.

10 days post-transfection and puromycin treatment, individual clonal cell lines were
selected and evaluated. Speed of growth was ascertained by approximate colony size after 10
days and categorized into four categories: Fast, Medium, Slow, and Super Slow. Those cell lines
categorized as Fast and Medium were transferred to a 24-well plate to allow further growth.
Slow speed cell lines were transferred 7 days later (17 days post-transfection), and Super Slow
speed cell lines were transferred 2 days after that (19 days post-transfection).
Once the cells were

Comparison of Rates of Passage for Parental
and Knockout Cell Lines

transferred to culture flasks, the

3.5

frequency of passage was taken.
The parental cell line (with all
cell lines normalized to its rate of
passage) was seen to have a
passage rate of half or less than
the passage rate of any knockout

Normalized Pass Rate
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Figure 9. Comparison of passage rates for parental and knockout cell lines.
The cells were passed at a frequency relative to their growth speed and the rate
at which they ran out of culture flask surface space. The fewer days between
passes, the faster the cells grow. All data is normalized to the ratio of passage.
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Further evaluation while the cells continued growing was done based on approximate size
of cells and adherence to the cell culture surfaces. Of the 14 cell lines categorized as Fast (within
all three sgRNA constructs), no cell line exhibited any abnormal morphology. These cell lines

Figure 10. Phenotypic differences between cell lines. HCT-116 (A) shows parental cell line
growth, 1MY2 (B) shows abnormal cell flask adherence, and 1SY5 (C) and 1SY1 (D) display
abnormally sized cells. All images were taken at 100x.
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phenotypes, with 7 of 8 exhibiting abnormal adherence (5 less adhered, 2 more adhered), and 3
of 8 exhibiting extra-large cells among the normal sized cells (as compared to the parental cell
line) (Examples in Figure 12). The 13 cell lines exhibiting Slow growth speed all exhibited some
sort of abnormal phenotype. 10 of the 13 exhibited extra-large cell sizes and 6 of the 13
demonstrate differing surface adherence (3 less and 3 more adhered). All 4 Super Slow cell lines
exhibited expanded cell size. It should be noted that, depending on the degree of largeness seen
in the cells, and the percentage of cells with this affliction could potentially interfere with visual
flask adherence observations, due to sheer inexperience with this type of cell.
Determining Knockout
PCR program and
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Figure 11. Confirmation of desired PCR product. Primers used to amplify the
region of intended knockout were used on genomic HCT-116 DNA to ensure
ample PCR product at the intended length in base pairs. Assumed length is above
each band, and ladder band values are underlined in red. Primer sets (above their
respective lanes) can be found in Appendix 1.

Knockout was suspected in all cells containing an abnormal phenotype and not suspected
in cell lines that did not exhibit the abnormal phenotype. As a result, only one cell line in the Fast

- 31 growth category was evaluated for knockout. As stated, PCR was only performed in the area of
attempted knockout – three different areas for the three different sgRNA constructs. As knockout
was only able to be confirmed in six cell lines, all transfected with sgRNA construct #1, those
results are shown, compared to the one Fast cell line, the parental cell line, and the one cell line
that does not contain a knockout, 1SSY1. Knockout was obtained in all confirmed cell lines by
way of frameshift, or indel, mutation. All cell lines show some sort of insert, and three of the six

Figure 12. Alignment of sequencing results of confirmed knockouts. Six cell lines (1SY1, 1SY2, 1SY5, 1SSY2,
1MY1, 1MY2) have confirmed knockouts by way of frameshift mutation (highlighted in blue), 1SSY1 can be
confirmed to have no knockout at this location, and knockout in 1FN1 is unable to be determined.

also show some sort of deletion (Figure 14).
Due to frameshift mutation in all cell lines except 1MY2, the protein product derived
from the mutant CUL3 mRNA is expected to be largely inaccurate, potentially creating a
premature STOP codon and translating all amino acids after the site of mutation in the wrong
open reading frame. 1MY2 would result in the addition of an amino acid to the sequence, which
could affect protein folding or interactions of the ligase with other proteins.
Changes in Metabolic Activity
MTS is an altered, more accurate form of the MTT assay (both named for the type of
tetrazolium salt used). This assay measures metabolic activity, and therefore cell growth and
survival, by the conversion of tetrazolium salt to formazan. This change is catalyzed by the
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cleavage results in a color change that is then read by a spectrophotometer (Buttke et al. 1993,
Denizot and Lang 1986).
Preliminary data (resulting from one run of the assay) suggests that CUL3 knockout has
resulted in an increase in metabolic activity (Figure 15). All cell lines with a confirmed knockout
had significantly higher formazan output than the parental cell line for the first two days. By the
fourth day, the parental cell line had caught up to the knockouts, indicating that all cell lines may
have tapered off in metabolic activity increase. This is usually the result of reaching spatial
constraints and commonly seen in the parental cell line.

Comparison of MTS Absorbance Rates per Cell Line
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Figure 13. Comparison of the MTS Absorbances of Various Cell Lines. The (490nm – 650nm) absorbances after
treatment with MTS CellTiter liquid of each knockout cell line (sans 1SY5) are compared day by day. The control
(HCT 116) is outlined with a dotted line.
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Off-Target Effects
An NCBI Blast search for the target sequence and PAM (both NGG and NAG) was
performed to locate sites within the human genome that may be targets of off-target cutting. The
Blast search resulted in five potential off-target cut sites in actual genes. Two other sites were
found in non-coding regions of the genome (Figure 16). Of the five potentially deleterious offtarget sites, only one had homology of over 90% to the original target sequence. Two had over
85% homology, but both had the NAG PAM, indicating that they might be less likely to bind
than a NGG counterpart.

Figure 14. Possible Off-Target Effects. The potential off target sequences compared to the P1 CUL3
target sequence used in the sgRNA CRISPR. NC1 & 2 are non-coding regions, RAVER2 is
Ribonucleotide PTB-binding 2, PEX1 is Peroxisomal biogenesis factor 1, LRPPRC is Leucine-rich PPR
motif containing protein, BBX is an HMG box transcription factor, and FOX1 is Forkhead box protein 1.
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EXPERIMENTAL FINDINGS
Morphological Changes
In every cell line with a confirmed knockout, morphological changes were seen. While
the specific changes vary from cell line to cell line, the majority of cell lines with confirmed
knockout exhibit a phenotype that would be expected of a CUL3 knockout.
The morphology seen could be due to CUL3’s effects on monoubiquitination of Aurora B
kinase, an enzyme involved in mitotic spindle stability and cytokinesis. Because of the function
of monoubiquitination as a modulator of protein function and localization (as opposed to
degradation targeted by
polyubiquitination), a CUL3
knockout essentially results in
knockout of Aurora B’s
secondary function and
localization (Maerki et al.
2010, Sumara et al. 2007).
Sumara et al.’s results using
RNAi to inhibit CUL3

Figure 15. Multinucleation due to CUL3 knockdown. (Sumara et al. 2007;
Used with permissions from Elsevier) RNAi that inhibits CUL3 function
results in multinucleated cells due to interference with normal Aurora B
function.

translation best exemplifies visually the resultant multinucleation and inhibited cytokinesis, seen
in Fig. 17 (2007). The mechanism by which this is occurring is elucidated by Maerki et al. (2009,
2010), where they posit a role for Aurora B monoubiquitination in aligning chromosomes to the
divisional plane. Aurora B degradation, similar to inactivation, has been shown to result in faulty
cytokinesis and multinucleation. Additionally, there is evidence that inhibition of normal Aurora
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centrosome but not connecting to a kinetochore) (Figure 4) (Kallio et al. 2002).
Because multinucleation and failed cytokinesis halts the cell cycle, Aurora B inhibition
could also be seen to slow the overall growth rate of a cell culture, which may explain the need
for less frequent passage in the knockout cell lines. We expect that if Aurora B was completely
inhibited, no cytokinsese would occur and the cells would not survive. However, though Aurora
B monoubiquitination is critical for cytokinesis and its inhibition, in all literature reviewed, it
does not seem to effect all cells in the culture identically. In this way, CUL3 knockout to disable
Aurora B monoubiquitination is more similar to a knockdown of Aurora B monoubiquitination.
This means that Aurora B function is severely inhibited, but not completely gone, allowing some
cells to survive and reproduce.
Metabolic Activity
The MTS assay used in this study is traditionally used as a method of ascertaining
proliferation of cells. Changes in metabolic activity can easily be correlated with changes in cell
growth in culture. This is assuming a relatively homogenized culture, with cells with equivalent
ATP requirements and mitochondrial output. However, if a mutation causes abnormal metabolic
activity, this assay no longer accurately measures the number and rate of cell proliferation.
Due to time constraints, the MTS assay had only one trial, with six individual wells
measured per cell line. Given that only one assay was performed, this assay will need to be
replicated to determine if the effects seen are reproducible. The trends here indicate that
metabolic activity increases in knockout cell lines, but one trial gives the conclusions drawn little
confidence. Therefore the first step before any concrete conclusions are drawn would be to rerun
the assay to the point where statistics can be run.
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CUL3 knockout cells would suddenly have higher metabolic activity. Likely, if the effects are
due to the knockout, the substrate responsible for increased metabolic activity has yet to be
discovered. There is also the possibility that the abnormal metabolic activity is due to off-target
Cas9 cutting.
Off-Target Effects
As previously stated, occasional off-target effects are unavoidable. Sequencing data of
the 1SSY1 cell line shows that no knockout occurred at the expected site. However, this cell line
still exhibited abnormal morphology and a substantially slowed growth rate (anecdotally). This
cell line is the most likely candidate for off-target cleavage. Of the seven off-target sites
identified in Figure 16, only four fit the criteria outlined by Ran et al. (2013), which includes
over 85% homology with the mutations at least 4 bp away from the PAM sequence. Only one is
within a non-coding region of DNA. The other three, PEX1, BBX, and FOX1, are the most
likely sites of off-target cutting, with priority to PEX1, as it retains the NGG PAM sequence and
has a higher percent homology (91% v. 86%) to the target sequence. Further study is needed to
determine whether or not these off-target sites are responsible for the abnormal morphology seen
in 1SSY1, and potentially other cell lines.

PERFECTING THE CUL3 KNOCKOUT
Alterations to the Current Approach
The CRISPR/Cas9 system, as described in the methods portion, produced six successful
KO-CUL3 cell lines. However, since six out of 41 total cell lines is a 14% success rate, the
knockout efficiency could be increased with alterations to the approach.
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per transfection in hopes that, if one target does not work, another may do better. In the archaea
and bacteria from which this system is derived, multiple protospacers targeting the same plasmid
or virus will be integrated into their genomes (Jinek et al. 2012). This gives the Cas9 more target
sequences at which to cleave and, theoretically, a more successful neutralization of the invasive
DNA. The beauty of the Cas9 enzyme is that once the template DNA for Cas9 is in the target
cell’s genome, the enzyme can cut anywhere, and in multiple places, as long as a crRNA
template(s) are provided.
Genome Editing versus Gene Silencing
In this study, gene silencing was the goal of the transfection process - mutation in the
gene to either shift its reading frame into nonsense or produce a premature stop codon. However,
another option exists - gene editing. This is done very similarly to gene silencing, where
transfection occurs, introducing the Cas9 enzyme and two sgRNA constructs, resulting in two
double-stranded breaks and excision of the area of interest. It also requires transfection of a
repair template, as the major difference occurs in the repair process. Where single DNA breaks
prefers the mutation-prone NHEJ (non-homologous end joining) process, DNA excision uses
homologous recombination. Homologous recombination uses the transfected template to repair
the break in a guided way. This template contains the gene edits. Single nucleotide differences
can be introduced with a single break, and large portions of the gene can be rewritten with two
breaks (caused by two differently targeted sgRNAs) (Ran et al. 2013).
With regards to CUL3, gene editing could be used to check the opposite of gene
knockout - a knockin - by altering the promoter to turn the gene constitutively on. If a knockout
results in slower growth, a knockin could result in accelerated growth. A knockin would likely
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be uninhibited, and potentially better. Knockin would also likely increase resistance of cells to
CPT (camptothecin chemotherapy) by decreasing cellular TOP1 concentration.
Temporary CUL3 Knockout
The use of a catalytically inactive Cas9 has been seen to create a reversible knockout, or
knockdown. The Cas9 still targets the gene of interest by way of sgRNA guidance, but instead of
catalyzing a double-stranded break, the Cas9 will bind to the target site and inhibit transcription
by simply getting in the way. Because no permanent mutation has occurred, the process, called
CRISPRi, is reversible (Qi et al. 2013). This could allow the researcher to inhibit CUL3, and
then remove the inhibition to see if the various phenotypes rectify themselves.

CUL3’S KNOWN ROLE IN CANCER
Database Results
CUL3 itself has been implicated as a driver gene in several types of human cancers,
including head and neck squamous cell carcinoma; lung, stomach, and prostate adenocarcinoma;
cutaneous melanoma; and esophageal carcinoma. In all cancers, the driver mutation resulted in a
loss of function of CUL3 (IntOGen). Many of the mutations (72.5%, according to COSMIC)
catalogued both by IntOGen and COSMIC result in a missense substitution mutation within the
CUL3 gene. In addition to missense mutations of the gene itself, mutation in the neddylation
protein Nedd8 has been found to affect cancer by way of controlling CUL3 function (IntOGen).
The frequency of CUL3/Nedd8 mutation in any of the experiments reporting CUL3/Nedd8
mutation was no more than 3-4% of the genotyped cancers. While CUL3 does seem to have a
role in driving cancer, it does so at a relatively infrequent rate.
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reference the data found in COSMIC indicating that CUL3 is known to mutate in CRC. While
the status of CUL3 as a driver gene in cancer is weak, CUL3 is still an intriguing therapeutic
target and diagnostic tool.
Cancer Treatments
Substrates of CUL3 have been linked to the effectiveness of certain types of
chemotherapies, giving CUL3 knockout cancers certain properties. CUL3 knockout makes it less
likely that an individual will acquire resistance to antitumor camptothecins (CPTs), a type of
chemotherapy. Sometimes, a cancer cell will become resistant to CPTs by down-regulating the
expression of topoisomerase I (TOP1), the target of the drug. This is sometimes done by
upregulating CUL3 and the ubiquitin-based degradation of TOP1 (Zhang et al. 2004B). Studies
have shown that ubiquitination of TOP1 is an important determinant in CPT sensitivity (Beretta
et al. 2013). This implies that inhibition of TOP1 degradation may be able to restore CPT
sensitivity to resistant cancers. CUL3 knockout inhibits TOP1 degradation by removing the
machinery to ubiquinate the TOP1, thus providing us with a potential avenue for rectifying CPT
resistance.
Cyclin E cellular concentration has been inversely correlated with breast cancer patient
survivability (Keyomarsi et al. 2002). Since cyclin E production is not really tissue specific, the
likelihood is high that colon cancers would demonstrate the same trends seen in breast cancer.
This indicates that a CUL3 knockout in colon cancer, which increases the cellular cyclin E by
not degrading it, will likely result in more aggressive cancers and higher overall lethality.
Aurora B kinase overexpression has been recently correlated with lung cancer lethality
(Takeshita et al. 2012). Again, Aurora B expression is also not tissue-specific, making the trends
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aneuploidy, or abnormal numbers of chromosomes, which often leads to increased malignancy
(Masafumi et al. 2012). By inhibiting Aurora B chromosomal localization by CUL3 knockout, an
Aurora B overexpression could be rectified.
Nrf2 expression has very recently been linked to gastric cancer and patient survivability.
The higher the expression of Nrf2, the more aggressive the cancer (Kawasaki et al. 2015). In
non-small-cell lung cancer, diallelic inactivation of KEAP1 (Nrf2’s adapter protein), and
therefore inhibition of Nrf2 degradation, results in higher rates of chemoresistance (Singh et al.
2006). A CUL3 knockout would increase expression of Nrf2, which should make the cancer
more aggressive overall, and more resistant to oxidative stress. CUL3 overexpression has
conversely been seen to decrease Nrf2 expression and increase breast cancer sensitivity to
oxidative stress and chemotherapies (Loignon et al. 2009). In this way, CUL3 overexpression
might become a therapeutic tool.
There is also the potential for utilizing the CUL3 ubiquitination mechanism as a type of
target. For example, to ensure overexpression of a gene, like TOP1, one would only need to
inhibit its adapter protein to turn off its degradation and increase cellular concentrations of TOP1
(Unfortunately, the adapter protein of TOP1 is as of yet undiscovered). CUL3’s many substrates
have different effects regarding cancer growth, many of which are contradictory to one another
when it comes to cancer growth and patient survivability. Therefore, CUL3 is likely not a good
target for cancer treatment, but rather its individual substrates are.
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Appendix 1. Primer Sequences
Primer Name:

Sequence

CUL3Exon4P1.1F

aagttgcacattgcttaagatc

CUL3Exon4P1.1R

cctttccgctctcttgcaatc

CUL3Exon4P1.2F

atgctcacaagaactgtactc

CUL3Exon4P1.2R

ccaatgtgctcaacattcaaac

CUL3Exon11P2.1F

gagatcgtgccattgcattc

CUL3Exon11P2.1R

ggaaattgctgtatgccagg

CUL3Exon11P2.2F

caacgagcgaaactctgtc

CUL3Exon11P2.2R

gctccttttgatcacgagg

CUL3Exon14P3.1F

ggagcccattagtttgagac

CUL3Exon14P3.1R

catctggaaagtggaaacttg

Appendix 2. PCR Program
2 minutes

45 seconds

45 seconds

30 seconds

5 minutes

95°C

95°C

50°C

73°C

73°C

25 cycles

Appendix 3. Raw Observational Data

Cell Line
Parental
1FN1
1FN2
1FN3
1FN4
1MN1

Guide
Sequence
None
C1
C1
C1
C1
C1

Growth Speed
(approximate)
Fast
Fast
Fast
Fast
Fast
Medium

Abnormal
Morphology?
No
No
No
No
No
No

Extra-Large
Cells

Abnormal
Adherence

- 48 1MY1
1MY2
1SY1
1SY2
1SY3
1SY4
1SY5
1SY6
1SSY1
1SSY2
1SSY3
2FN1
2FN2
2FN3
2FN4
2FN5
2MN1
2MY1
2MY2
2SY1
2SY2
2SY3
2SSY1
3FN1
3FN2
3FN3
3FN4
3FN5
3MN1
3MY1
3MN2
3MY2
3MY3
3SY3
3SY4
3SY1
3SY2

C1
C1
C1
C1
C1
C1
C1
C1
C1
C1
C1
C2
C2
C2
C2
C2
C2
C2
C2
C2
C2
C2
C2
C3
C3
C3
C3
C3
C3
C3
C3
C3
C3
C3
C3
C3
C3

Medium
Medium
Slow
Slow
Slow
Slow
Slow
Slow
Super Slow
Super Slow
Super Slow
Fast
Fast
Fast
Fast
Fast
Medium
Medium
Medium
Slow
Slow
Slow
Super Slow
Fast
Fast
Fast
Fast
Fast
Medium
Medium
Medium
Medium
Medium
Slow
Slow
Slow
Slow

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

X
X
X
X
X
X
X
X
X
X
X

X
X

X

X
X
X
X

X

X
X
X
X
X
X
X

X
X
X
X

Table 2. Raw Data on Growth Speed and Abnormal Morphology. Represented above is the categorization
of individual cell lines from subcloning. Cell lines were assessed for relative growth speed, abnormal cell
size, and abnormal flask adherence (either over-adhered or under-adhered).

- 49 Appendix 4. GoTaq Green Mastermix Protocols (Provided by Promega)
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